Biosimilars – Market Events And Forecast – Forecast Methodology And General Market Assumptions
In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in these therapy areas and countries totaled approximately $15 billion. Throughout our 2021-2031 forecast period, increasing numbers of branded biologics are set to lose patent protection, and biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.
Table of contents
- Biosimilars - Market Events And Forecast - Forecast Methodology And General Market Assumptions
- Brands included in market forecast
- General market assumptions
- Clinical trials
- Approval times and market launch delays
- Key regulatory review and launch delay assumptions
- United States
- EU5
- Japan
- Indication extrapolation
- Pharmacy-level substitution
- Biosimilar pricing
- Reference-brand pricing
- Biosimilar adoption rates
- Key assumptions
- Biosimilar adoption rates
- United States
- EU5
- Japan
- Clinical trials
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.
Yashu Malhotra, M.Pharm., is an analyst on the Biosimilars and Oncology teams at Clarivate. Previously, she was a senior analyst in the life sciences department at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.